bioAffinity Technologies, Inc.
NCM: BIAFLive Quote
About bioAffinity Technologies, Inc.
Healthcare
Diagnostics & Research
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
📊 Fundamental Analysis
bioAffinity Technologies, Inc. demonstrates a profit margin of -242.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -27.8% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -301.8%, which indicates that capital utilization is currently under pressure.
At a current price of $3.35, BIAF currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $0.69 - $17.43).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$6.85M
Trailing P/E
--
Forward P/E
-5.58
Beta (5Y)
-0.81
52W High
$17.43
52W Low
$0.69
Avg Volume
8.96M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App